Five Prime Therapeutics (FPRX) Tops Q4 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Five Prime Therapeutics (FPRX) PT Lowered to $25 at Nomura/Instinet
February 28, 2018 5:52 AM ESTNomura/Instinet lowered its price target on Five Prime Therapeutics (NASDAQ: FPRX) to $25.00 (from $94.00) while maintaining a Buy rating.
Analyst Chris Marai comments "On the call, management provided limited color on meaningful updates from the cabira program. We are concerned that future... More
